



Corporate Identity No. (CIN No.) L24230GJ1995PLC025878

Cadila
Healthcare Limited**Regd. Office :**

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com

April 15, 2014

Bombay Stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Attention: Mr. Sanjay Golecha
Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

✓ **National Stock Exchange of India Ltd.**
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra – (East)
Mumbai – 400 051

Attention: Famroze Pochara
Asst. Vice President

Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad – 380 015

Fax No. 079 - 26308877

Re.: Press Release

Dear Sir / Madam

We enclose herewith a copy of press release dated April 15, 2014 under the title “**Cadila Healthcare Limited Announces Settlement with Depomed on Gralise®**” to be released in the News Papers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED

UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above.



Release

Press Release

Release

Press Release

Cadila Healthcare Limited Announces Settlement with Depomed on Gralise®

Ahmedabad, April 15, 2014

Cadila Healthcare Limited, a global pharmaceuticals company, and Zydus Pharmaceuticals (USA), Inc., a leading generic pharmaceutical company in the United States, today announced that they have entered into a settlement agreement with Depomed, Inc. to settle their ongoing patent infringement litigation related to Gralise® (gabapentin) 300 mg and 600 mg tablets. The settlement permits Cadila and Zydus to begin selling generic versions of Gralise® on January 1, 2024, or earlier under certain circumstances. Other terms of the settlement were not disclosed.

The agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs 16,000 people worldwide and is dedicated to creating healthier communities globally. Zydus Cadila is the only Indian pharma company to launch its own patented NCE – Lipaglyn™, the world's first drug to be approved for the treatment of diabetic dyslipidemia. Zydus aspires to be a research-based pharmaceutical company by 2020.